Natera Inc. logo

Natera Inc.

NTRA | NASDAQ
Chart Builder DCF Calculator
$370.39
+$1 (+0.27%)
Sep 21, 2026, 1:51 PM ET · Market open

Company Profile

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Key Executives

Name Position
Steven Leonard Chapman Chief Executive Officer & Director
Daniel Rabinowitz Secretary & Chief Legal Officer
Michael Brophy Chief Financial Officer
Rishi Kacker Chief Technology Officer
Eric A. Evans Chief Scientific Officer
John Fesko President & Chief Business Officer
Jonathan Sheena Co-Founder & Director
Matthew Rabinowitz Co-Founder & Executive Chairman
Olesya A. Anisimova Chief Accounting Officer
Solomon Moshkevich President of Clinical Diagnostics

Latest SEC Filings

Date Type Title
Sep 03, 2026 4 Filing
Sep 03, 2026 4 Filing
Aug 28, 2026 4 Filing
Aug 14, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 07, 2026 4 Filing
Aug 07, 2026 4 Filing
Aug 07, 2026 S-8 Filing
Aug 07, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
View All SEC Filings
Natera Inc.
Natera Inc. logo
Country United States
IPO Date Jun 30, 2015
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 6,138
CEO Steven Leonard Chapman

Contact Details

13011 McCallen Pass Building A Austin, Texas 78753 United States

Stock Details

Ticker Symbol NTRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001604821
CUSIP Number 632307104
ISIN Number US6323071042
SIC Code 8071

© 2026 bestshares.com. All rights reserved.